作为癌症治疗中的新兴疗法,氧酶增殖器激活受体对抗剂
Snehal Misal1, Vijay M Patil1, C S Ramaa1
1Department of Pharmaceutical Chemistry, Bharati Vidyapeeth's College of Pharmacy, Sector-8, CBD Belapur, Navi Mumbai 400614, India.
氧酶增殖器激活受体 (PPAR) 抗剂通过破坏瘤生长和新陈代谢,在癌症治疗中表现有前途. 对于这些新型抗癌剂的临床转化,需要进一步的研究.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症是全球主要的死亡原因,需要新的治疗策略.
- 过氧体增殖器激活受体 (PPARs) 调节包括新陈代谢和炎症在内的关键细胞过程,并与瘤进展有关.
- 虽然已经研究了PPAR激动剂,但PPAR抗剂正在通过向瘤性途径而成为有前途的抗癌药物.
研究的目的:
- 审查药物化学,分子机制,以及用于癌症治疗的PPAR抗体的药理学发展.
- 突出PPAR抗剂在精密瘤学中的潜在临床应用.
主要方法:
- 在癌症研究中对PPAR抗剂的综合文献综述.
- 分析特定的PPARα,PPARβ/δ和PPARγ抗剂及其作用机制.
- 评估组合策略及其协同效应.
主要成果:
- PPAR抗体选择性调节瘤性途径,损害瘤代谢,血管生成,增殖和转移.
- 像GW6471,TPST-1120,GSK0660,ST247,T0070907和GW9662这样的特定抗剂表现出明显的抗癌作用.
- 与化疗,免疫疗法或向药物的联合疗法显示出增强的抗瘤疗效和克服耐药性.
- PPAR抗剂还调节瘤微环境和免疫反应.
结论:
- PPAR抗剂是一种多方面的治疗方法,具有显著的抗癌潜力.
- 需要进行进一步的研究,以优化选择性,药理动力学和药物输送,以获得成功的临床转化.
- 精细的药物设计和精心设计的临床试验对于将PPAR抗剂整合到精确瘤学中至关重要.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peroxisomes
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
